消化

订阅

MedSci主页 / 所有栏目 / 消化

EASL 2014：Sofosbuvir的SVR率与患者阴性预测因素相关

2014-05-13 佚名 dxy

HCV病毒
关注

sofosbuvir（SOF）的3期研究表明，其对于各种HCV基因型和耐药性相关突变均有疗效。但仍需要进一步寻找与药物疗效相关的宿主和病毒因素，该研究结果公布于2014年4月11日在伦敦举行的EASL2014会议上。 该研究共纳入了6个研究队列。其中339例初治的HCV基因1型感染者来自ATOMIC和NEUTRINO队列。这些患者使用12周SOF +PegIFN+RBV方案进行治疗。 285例初治

sofosbuvir（SOF）的3期研究表明，其对于各种HCV基因型和耐药性相关突变均有疗效。但仍需要进一步寻找与药物疗效相关的宿主和病毒因素，该研究结果公布于2014年4月11日在伦敦举行的EASL2014会议上。

该研究共纳入了6个研究队列。其中339例初治的HCV基因1型感染者来自ATOMIC和NEUTRINO队列。这些患者使用12周SOF +PegIFN+RBV方案进行治疗。

285例初治或经治的HCV2型感染者来自FISSION，POSITRON，FUSION和VALENCE研究，接受12周SOF+利巴韦林治疗。其中244例初治的基因3型HCV感染者来自VALENCE研究。他们接受24周SOF +利巴韦林治疗。最后通过单因素回归分析和多因素回归分析寻找与药物疗效相关的基线宿主和病毒因素。

多因素回归分析发现，6个独立因素与病毒学复发有关：男性，体重≥75千克，基线HCVRNA≥800,000IU/mL，肝硬化，IL28B非CC基因型和既往治疗失败者。所有基因型患者当≤3阴性预测因子时，SVR率在90％以上。当出现5或6个阴性预测因子时，SVR率递减。

该研究表明，当前的SOF方案是高度有效的。那些有5或6个阴性预测因子的患者SVR率比较低。下一步的研究重点是需要解决现有最难治愈的人群。

版权声明：
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料，版权均属于梅斯医学所有。非经授权，任何媒体、网站或个人不得转载，授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章，或“梅斯号”自媒体发布的文章，仅系出于传递更多信息之目的，本站仅负责审核内容合规，其内容不代表本站立场，本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系，我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1264205, encodeId=b1961264205ff, content=<a href='/topic/show?id=daf1100226fb' target=_blank style='color:#2F92EE;'>#预测因素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100226, encryptionId=daf1100226fb, topicName=预测因素)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a57b78, createdName=朱睿睿, createdTime=Thu May 15 07:06:00 CST 2014, time=2014-05-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1412534, encodeId=aceb14125343d, content=<a href='/topic/show?id=ebcd6442dc' target=_blank style='color:#2F92EE;'>#EASL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6442, encryptionId=ebcd6442dc, topicName=EASL)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a0c52872504, createdName=kord1983, createdTime=Thu May 15 07:06:00 CST 2014, time=2014-05-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1416411, encodeId=6748141641168, content=<a href='/topic/show?id=e9b316951a2' target=_blank style='color:#2F92EE;'>#SVR#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16951, encryptionId=e9b316951a2, topicName=SVR)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3f113178185, createdName=w363522450, createdTime=Thu May 15 07:06:00 CST 2014, time=2014-05-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1500771, encodeId=20a11500e71a6, content=<a href='/topic/show?id=4a27165246a' target=_blank style='color:#2F92EE;'>#Sofosbuvir#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16524, encryptionId=4a27165246a, topicName=Sofosbuvir)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=50d29462111, createdName=Tommy1952, createdTime=Thu May 15 07:06:00 CST 2014, time=2014-05-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1519196, encodeId=00e4151919619, content=<a href='/topic/show?id=2082286e7b' target=_blank style='color:#2F92EE;'>#ASL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2867, encryptionId=2082286e7b, topicName=ASL)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c1a311248160, createdName=lq1771, createdTime=Thu May 15 07:06:00 CST 2014, time=2014-05-15, status=1, ipAttribution=)]
    2014-05-15 朱睿睿

    #预测因素#

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=1264205, encodeId=b1961264205ff, content=<a href='/topic/show?id=daf1100226fb' target=_blank style='color:#2F92EE;'>#预测因素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100226, encryptionId=daf1100226fb, topicName=预测因素)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a57b78, createdName=朱睿睿, createdTime=Thu May 15 07:06:00 CST 2014, time=2014-05-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1412534, encodeId=aceb14125343d, content=<a href='/topic/show?id=ebcd6442dc' target=_blank style='color:#2F92EE;'>#EASL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6442, encryptionId=ebcd6442dc, topicName=EASL)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a0c52872504, createdName=kord1983, createdTime=Thu May 15 07:06:00 CST 2014, time=2014-05-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1416411, encodeId=6748141641168, content=<a href='/topic/show?id=e9b316951a2' target=_blank style='color:#2F92EE;'>#SVR#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16951, encryptionId=e9b316951a2, topicName=SVR)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3f113178185, createdName=w363522450, createdTime=Thu May 15 07:06:00 CST 2014, time=2014-05-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1500771, encodeId=20a11500e71a6, content=<a href='/topic/show?id=4a27165246a' target=_blank style='color:#2F92EE;'>#Sofosbuvir#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16524, encryptionId=4a27165246a, topicName=Sofosbuvir)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=50d29462111, createdName=Tommy1952, createdTime=Thu May 15 07:06:00 CST 2014, time=2014-05-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1519196, encodeId=00e4151919619, content=<a href='/topic/show?id=2082286e7b' target=_blank style='color:#2F92EE;'>#ASL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2867, encryptionId=2082286e7b, topicName=ASL)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c1a311248160, createdName=lq1771, createdTime=Thu May 15 07:06:00 CST 2014, time=2014-05-15, status=1, ipAttribution=)]
    2014-05-15 kord1983

    #EASL#

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1264205, encodeId=b1961264205ff, content=<a href='/topic/show?id=daf1100226fb' target=_blank style='color:#2F92EE;'>#预测因素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100226, encryptionId=daf1100226fb, topicName=预测因素)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a57b78, createdName=朱睿睿, createdTime=Thu May 15 07:06:00 CST 2014, time=2014-05-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1412534, encodeId=aceb14125343d, content=<a href='/topic/show?id=ebcd6442dc' target=_blank style='color:#2F92EE;'>#EASL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6442, encryptionId=ebcd6442dc, topicName=EASL)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a0c52872504, createdName=kord1983, createdTime=Thu May 15 07:06:00 CST 2014, time=2014-05-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1416411, encodeId=6748141641168, content=<a href='/topic/show?id=e9b316951a2' target=_blank style='color:#2F92EE;'>#SVR#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16951, encryptionId=e9b316951a2, topicName=SVR)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3f113178185, createdName=w363522450, createdTime=Thu May 15 07:06:00 CST 2014, time=2014-05-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1500771, encodeId=20a11500e71a6, content=<a href='/topic/show?id=4a27165246a' target=_blank style='color:#2F92EE;'>#Sofosbuvir#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16524, encryptionId=4a27165246a, topicName=Sofosbuvir)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=50d29462111, createdName=Tommy1952, createdTime=Thu May 15 07:06:00 CST 2014, time=2014-05-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1519196, encodeId=00e4151919619, content=<a href='/topic/show?id=2082286e7b' target=_blank style='color:#2F92EE;'>#ASL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2867, encryptionId=2082286e7b, topicName=ASL)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c1a311248160, createdName=lq1771, createdTime=Thu May 15 07:06:00 CST 2014, time=2014-05-15, status=1, ipAttribution=)]
    2014-05-15 w363522450

    #SVR#

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1264205, encodeId=b1961264205ff, content=<a href='/topic/show?id=daf1100226fb' target=_blank style='color:#2F92EE;'>#预测因素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100226, encryptionId=daf1100226fb, topicName=预测因素)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a57b78, createdName=朱睿睿, createdTime=Thu May 15 07:06:00 CST 2014, time=2014-05-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1412534, encodeId=aceb14125343d, content=<a href='/topic/show?id=ebcd6442dc' target=_blank style='color:#2F92EE;'>#EASL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6442, encryptionId=ebcd6442dc, topicName=EASL)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a0c52872504, createdName=kord1983, createdTime=Thu May 15 07:06:00 CST 2014, time=2014-05-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1416411, encodeId=6748141641168, content=<a href='/topic/show?id=e9b316951a2' target=_blank style='color:#2F92EE;'>#SVR#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16951, encryptionId=e9b316951a2, topicName=SVR)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3f113178185, createdName=w363522450, createdTime=Thu May 15 07:06:00 CST 2014, time=2014-05-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1500771, encodeId=20a11500e71a6, content=<a href='/topic/show?id=4a27165246a' target=_blank style='color:#2F92EE;'>#Sofosbuvir#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16524, encryptionId=4a27165246a, topicName=Sofosbuvir)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=50d29462111, createdName=Tommy1952, createdTime=Thu May 15 07:06:00 CST 2014, time=2014-05-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1519196, encodeId=00e4151919619, content=<a href='/topic/show?id=2082286e7b' target=_blank style='color:#2F92EE;'>#ASL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2867, encryptionId=2082286e7b, topicName=ASL)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c1a311248160, createdName=lq1771, createdTime=Thu May 15 07:06:00 CST 2014, time=2014-05-15, status=1, ipAttribution=)]
    2014-05-15 Tommy1952

    #Sofosbuvir#

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=1264205, encodeId=b1961264205ff, content=<a href='/topic/show?id=daf1100226fb' target=_blank style='color:#2F92EE;'>#预测因素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100226, encryptionId=daf1100226fb, topicName=预测因素)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a57b78, createdName=朱睿睿, createdTime=Thu May 15 07:06:00 CST 2014, time=2014-05-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1412534, encodeId=aceb14125343d, content=<a href='/topic/show?id=ebcd6442dc' target=_blank style='color:#2F92EE;'>#EASL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6442, encryptionId=ebcd6442dc, topicName=EASL)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a0c52872504, createdName=kord1983, createdTime=Thu May 15 07:06:00 CST 2014, time=2014-05-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1416411, encodeId=6748141641168, content=<a href='/topic/show?id=e9b316951a2' target=_blank style='color:#2F92EE;'>#SVR#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16951, encryptionId=e9b316951a2, topicName=SVR)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3f113178185, createdName=w363522450, createdTime=Thu May 15 07:06:00 CST 2014, time=2014-05-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1500771, encodeId=20a11500e71a6, content=<a href='/topic/show?id=4a27165246a' target=_blank style='color:#2F92EE;'>#Sofosbuvir#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16524, encryptionId=4a27165246a, topicName=Sofosbuvir)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=50d29462111, createdName=Tommy1952, createdTime=Thu May 15 07:06:00 CST 2014, time=2014-05-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1519196, encodeId=00e4151919619, content=<a href='/topic/show?id=2082286e7b' target=_blank style='color:#2F92EE;'>#ASL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2867, encryptionId=2082286e7b, topicName=ASL)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c1a311248160, createdName=lq1771, createdTime=Thu May 15 07:06:00 CST 2014, time=2014-05-15, status=1, ipAttribution=)]
    2014-05-15 lq1771

    #ASL#

    0

相关资讯

J Virol：我国建立HCV感染性DNA克隆

记者日前从中科院上海巴斯德所获悉，该所钟劲课题组和上海交通大学附属瑞金医院谢青课题组合作，建立了我国首例丙型肝炎病毒（HCV）感染性DNA克隆，为下一步抗HCV药物和疫苗的研发带来极大便利。相关成果在线发表于《病毒学杂志》。【原文下载】 HCV细胞感染模型对于HCV生物学研究、抗病毒药物和疫苗研发具有重要作用，其中HCV感染性cDNA克隆的建立很关键。由于HCV基因组的变异很大，不同基因

EASL 2014：慢性HCV患者治疗决策相关的合并症

基于干扰素的慢性丙型肝炎（HCV）的治疗方案有很多副作用和禁忌症，从而限制了该治疗方案的运用。本研究的目的是：1）比较的那些使用或不使用双重疗法（聚乙二醇干扰素+利巴韦林）或三联疗法（特拉匹韦或boceprevir+聚乙二醇干扰素+利巴韦林）治疗的HCV感染者的临床特征； 2）确定无法治疗的显著预测因子。 研究结果表明，与治疗显著相关的因素包括年龄45-65岁，男性，肝硬化，艾滋病，非酒精性脂肪性

Hepatology：不同HCV感染者对治疗的敏感性差异的机制

肝脏干扰素（IFN）-刺激相关基因（ISG）的上调与白细胞介素（IL）28B在rs8099917上少数的基因型（MI）TG/GG有较强的关联。而rs8099917的基因型与干扰素的疗效相关，相对少数的基因型TG/GG对治疗不敏感。当基因型为相对多数基因型（MA）TT时，病人对治疗敏感。这背后的机制尚究竟如何？ 来自日本金泽大学医学院的研究人员通过ISG表达量的分析，发现IL28B基因型为（MI）

Gut：HCV治疗的新进展

研究要点 1.sofosbuvir将成为第一个治疗HCV1型感染的RNA聚合酶抑制剂。 2.Sofosbuvi对所有基因型的HCV都有强大的抗病毒活性。 3.sofosbuvir将成为第一个治疗HCV1型感染的RNA聚合酶抑制剂。在临床II期和III期的试验中，sofosbuvir可以作为多种（包含或不包含IFNα）治疗方案的一部分。其对所有HCV

EASL 2014：DCV+SOF可有效治疗HCV基因1,2,3型感染者

超过90％各种HCV基因型感染患者在使用DCV60mg+ SOF400mg每天±利巴韦林每天两次进行治疗，在12或24周后达到了持续性病毒学反应。该研究报道的是所有患者的耐药性检测结果。 该研究共纳入了211例患者。（126例为基因型1型的初治患者，44 例为基因型2/3初治患者，41例基因型1型患者既往进行telaprevir或boceprevir治疗）。研究人员对基线和治疗失败的病人进行测序，

EASL 2014：含SOF/LDV方案可有效治疗HCV基因1型初治患者

ION-3是一项非盲的3期临床研究，旨在评估较短的治疗时间内，固定剂量的sofosbuvir（SOF）400毫克/ ledipasvir（LDV）90毫克联合或不联合利巴韦林（RBV）治疗，对HCV基因1型初治非肝硬化患者的有效性和安全性。 研究将患者随机分配接受SOF / LDV±利巴韦林治疗8周或SOF / LDV 治疗12周。根据HCV亚型随机化分层。主要治疗终点为SVR12。 共647例患